Posted by Michael Wonder on 07 Mar 2017
Institute for Clinical and Economic Review posts draft scoping document on treatments for ovarian cancer
6 March 2017 - Document will be open to public comment until 27 March 2017.
March 6, 2017- The Institute for Clinical and Economic Review (ICER) has posted a Draft Scoping Document that will shape an upcoming report on poly (ADP-ribose) polymerase (PARP) inhibitors for treatment of ovarian cancer.
ICER's report is expected to review the evidence on rucaparib (Rubraca, Clovis Oncology), niraparib (Tesaro), and olaparib (Lynparza, AstraZeneca). Report analyses will also provide information on the cost-effectiveness and potential short-term budget impact of the therapies.
The Draft Scoping Document will be open to public comment for three weeks until 27 March 2017 at 5 pm CT.
